MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026

The company’s CEO Michael Castagna said that with two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation.

• MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes.
• H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update.
• The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."

MannKind Corporation (MNKD) on Thursday said that it expects two high potential launches going into 2026, driving investor optimism and sending shares up 2%. 

“With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation,” CEO Michael Castagna said, while adding that the company closed 2025 “on a high note” with its acquisition of scPharmaceuticals.

MannKind’s Potential Launches

MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes. The U.S. Food and Drug Administration is expected to rule on the application by May 29 and if approved, it would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy, the company said.

The company is also eyeing approval for its FUROSCIX ReadyFlow Autoinjector, developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX On-body Infusor. Furosemide is used for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).

Analyst Weighs In

H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. The price target represents a potential upside of about 88% from the stock's closing price on Wednesday. 

The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around MNKD shares jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.

A Stocktwits user dismissed the company’s Thursday update as “another pump and dump.”

MNKD stock has dropped 3% over the past 12 months. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<